Skip to main content

Medicare Part B Prior Authorization

Medicare Drug Policy
Policy Effective: 03/03/2025

Part B Prior Authorization Criteria for Approval

The requested Part B medication will be approved when BOTH of the following are met:

  1. ONE of the following: 
    1. There is an applicable national coverage determination (NCD) or local coverage determination (LCD) from the Medicare Administrative Contractor (MAC) for the jurisdiction and the patient meets all of the requirements listed within the NCD or LCD OR
    2. There is NOT an applicable NCD or LCD and the requested medication is being used according to FDA labeling or in accordance with a CMS supported compendia (i.e., NCCN, Clinical Pharmacology, Lexicomp Lexi-Drugs, Merative Micromedex, & AHFS-DI) or published peer-reviewed literature AND
  2. ONE of the following: 
    1. The requested medication is being evaluated for approval for the first time OR
    2. The request is for continuation of therapy and the patient has shown beneficial response to therapy

Length of Approval: See Table 1 below

NOTES: 

  • Length of approval may be shorter due to provider network participation status.

Table 1: Part B Prior Authorization

Bevacizumab (Oncology)

HCPCSMedicationLength of ApprovalNCD/LCD
Q5107Mvasi12 monthsN/A
Q5118Zirabev12 monthsN/A

Trastuzumab

HCPCSMedicationLength of ApprovalNCD/LCD
Q5117Kanjinti12 monthsN/A
Q5116Trazimera12 monthsN/A

Rituximab

HCPCSMedicationLength of ApprovalNCD/LCD
Q5119Ruxience12 monthsL35026
Q5115Truxima12 monthsL35026

Long-Acting Colony Stimulating Factors

HCPCSMedicationLength of ApprovalNCD/LCD
Q5108Fulphila12 monthsL37176
Q5122Nyvepria12 monthsL37176

Short-Acting Colony Stimulating Factors

HCPCSMedicationLength of ApprovalNCD/LCD
J2820Leukine12 monthsL37176
Q5110Nivestym12 monthsL37176
Q5101Zarxio12 monthsL37176

Immune Globulins

HCPCSMedicationLength of ApprovalNCD/LCD
J1551Cutaquig (SC)12 monthsL33794
J1569Gammagard Liquid (IV or SC)12 months

L34580

L33794

J1566Gammagard S/D (IV)12 monthsL34580
J1561Gammaked (IV or SC)12 months

L34580

L33794

J1561Gamunex-C (IV or SC)12 months

L34580

L33794

J1559Hizentra (SC) 12 monthsL33794
J1575HyQvia (SC)12 monthsL33794
J1599Immune Globulin, intravenous, not otherwise specified12 monthsL34580
J1568Octagam (IV)12 monthsL34580
J1459Privigen (IV)12 monthsL34580
J1558Xembify (SC)12 monthsL33794

Infliximab

HCPCSMedicationLength of ApprovalNCD/LCD
Q5121Avsola12 monthsL35677
Q5103Inflectra12 monthsL35677

Miscellaneous

HCPCSMedicationLength of ApprovalNCD/LCD
J3490Empaveli12 monthsN/A

J3590

C9399

Enspryng12 monthsN/A
J2507Krystexxa12 monthsN/A
J0896Reblozyl12 monthsN/A
J9333Rystiggo12 monthsN/A

G2082

G2083

Spravato6 monthsN/A
J3241Tepezza6 monthsN/A
J1303Ultomiris12 monthsN/A
J1823Uplizna12 monthsN/A
J9332Vyvgart12 monthsN/A
J9334Vyvgart Hytrulo12 monthsN/A

*See separate medical drug policies for the following drugs: Amvuttra, Onpattro and Oxlumo.

Revision History

12/11/2024:

  • Trastuzumab
    • Removed HCPCS code Q5114 for Ogivri
    • Added HCPCS code Q5116 for Trazimera
  • Long-Acting Colony Stimulating Factors 
    • Added HCPCS code Q5108 for Fulphila
    • Added HCPCS code Q5122 for Nyvepria
    • Removed HCPCS code Q5111 for Udenyca, Udenyca Onbody
    • Removed HCPCS code Q5120 for Ziextenzo
  • Immune Globulins
    • Removed HCPCS code J1599 for Alyglo
    • Removed HCPCS code J1554 for Asceniv
    • Removed HCPCS code J1556 for Bivigam
    • Removed HCPCS code J1555 for Cuvitru
    • Removed HCPCS code J1572 for Flebogamma
    • Removed HCPCS code J1557 for Gammaplex
    • Removed HCPCS code J1576 for Panzyga